<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03333187</url>
  </required_header>
  <id_info>
    <org_study_id>MMM 02 study / RuxoAlloStudy</org_study_id>
    <nct_id>NCT03333187</nct_id>
  </id_info>
  <brief_title>Ruxolitinib vs Allogeneic SCT for Patients With Myelofibrosis According to Donor Availability</brief_title>
  <official_title>Ruxolitinib Versus Allogeneic Stem Cell Transplantation for Patients With Myelofibrosis According to Donor Availability: A Prospective Phase II Trial (MMM 02 Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clinical Trial Center North (CTC North GmbH &amp; Co. KG)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitätsklinikum Hamburg-Eppendorf</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study will be a multicenter, prospective phase II-study comparing efficacy of&#xD;
      allogeneic SCT for patients with myelofibrosis who have a suitable stem cell donor after a 3&#xD;
      months Ruxolitinib induction therapy with patients who lack a suitable stem cell donor and&#xD;
      will continue to receive Ruxolitinib.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a multicenter, prospective phase II-study compares efficacy of allogeneic SCT&#xD;
      for patients with myelofibrosis who have a suitable stem cell donor after a 3 months&#xD;
      Ruxolitinib induction therapy with patients who lack a suitable stem cell donor and will&#xD;
      continue to receive Ruxolitinib.&#xD;
&#xD;
      In this study will further assess and compare the safety and efficacy of study treatments/&#xD;
      induction therapy in both study arms on spleen reduction, improvement of constitutional&#xD;
      symptoms, QOL, toxicity, fibrosis regression, development of GvHD as well as chimerism,&#xD;
      engraftment, relapse incidence, disease related mortality, outcome and overall survival.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 21, 2016</start_date>
  <completion_date type="Anticipated">October 2025</completion_date>
  <primary_completion_date type="Anticipated">October 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Treatment A (only with a suitable stem cell donor):&#xD;
Allogeneic SCT after 3 months of Ruxolitinib induction therapy&#xD;
Treatment B:&#xD;
Ruxolitinib continuous therapy</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event free survival</measure>
    <time_frame>3 years</time_frame>
    <description>Compare to event free survival of patients at 3 years after allogeneic SCT and in Ruxolitinib continuous therapy in patients without a suitable donor</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Spleen reduction</measure>
    <time_frame>3 months</time_frame>
    <description>Ultrasound measurement Spleen size, reduction of Spleen size after 3 months Ruxolitinib induction therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of constitutional symptoms</measure>
    <time_frame>3 months</time_frame>
    <description>Improvement of constitutional symptoms (Loose of weight and night sweat) after 3 months Ruxolitinib induction therapy, questionnaire, medical history</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of bone marrow fibrosis</measure>
    <time_frame>3 months</time_frame>
    <description>bone marrow histology, Improvement of bone marrow fibrosis after 3 months of Ruxolitinib induction therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute graft-versus-host disease</measure>
    <time_frame>Day +100 after allogeneic SCT</time_frame>
    <description>Incidence of acute graft-versus-host disease on Day +100 after allogeneic SCT according to the Glucksberg scale revised by Przepiorka</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic graft-versus-host disease</measure>
    <time_frame>1, 2 and 3 years after allogeneic SCT</time_frame>
    <description>Incidence of chronic graft-versus-host disease according to the NIH consensus criteria of Filipovich et al. at 1, 2 and 3 years after allogeneic SCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity of Ruxolitinib</measure>
    <time_frame>till 3 years</time_frame>
    <description>Toxicity of Ruxolitinib scored according to NCI CTCAE, Version 4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity of conditioning therapy</measure>
    <time_frame>till 3 years</time_frame>
    <description>Toxicity of conditioning therapy scored according to NCI CTCAE, Version 4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse</measure>
    <time_frame>3 years</time_frame>
    <description>Cumulative incidence of relapse at 3 years after allogeneic SCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-related mortality</measure>
    <time_frame>3 years</time_frame>
    <description>Disease-related mortality at 3 years after allogeneic SCT and Ruxolitinib continuous therapies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-relapsed mortality</measure>
    <time_frame>1 and 3 years</time_frame>
    <description>Non-relapsed mortality at 1 and 3 years after allogeneic SCT and Ruxolitinib continuous therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Discontinuation rate</measure>
    <time_frame>3 years</time_frame>
    <description>Discontinuation rate at 3 years after Ruxolitinib continuous therapy (End of study)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Sorror Risk Score</measure>
    <time_frame>at baseline</time_frame>
    <description>Evaluation of Sorror Risk Score on outcome after allogeneic SCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chimerism on relapse</measure>
    <time_frame>30d, 100d, 180 d, 1 year, 2 years and 3 years</time_frame>
    <description>Chimerism Analyse, Impact of chimerism on relapse incidence after allogeneic SCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone marrow fibrosis regression</measure>
    <time_frame>30d, 100d, 1 year, and 3 years</time_frame>
    <description>bone marrow histology, Evaluation of bone marrow fibrosis regression after allogeneic SCT at 30d, 100d, 1 year, and 3 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone marrow fibrosis regression</measure>
    <time_frame>30d, 100d, 1 year and 3 years</time_frame>
    <description>bone marrow histology, Evaluation of bone marrow fibrosis regression after Ruxolitinib continuous therapy at 30d, 100d, 1 year and 3 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of QOL (FACT-BMT)</measure>
    <time_frame>baseline, at transplantation, +180d, +1 year, +2 years and +3 years</time_frame>
    <description>Questionnaire, Evaluation of QOL (FACT-BMT) before Ruxolitinib induction therapy (= baseline), at transplantation, and after transplantation at 6m, 1 year, 2 years and 3 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of QOL (MPN-SAF-TSS)</measure>
    <time_frame>baseline, at transplantation, +180d, +1 year, +2 years and +3 years</time_frame>
    <description>Questionaire, Evaluation of QOL (MPN-SAF-TSS) before Ruxolitinib induction therapy (= baseline), at transplantation, and after transplantation at 6m, 1 year, 2 years and 3 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of QOL (FACT-BMT)</measure>
    <time_frame>baseline, confinement to Ruxolitinib continous therapy, +180d, +1 year, +2 years and +3 years</time_frame>
    <description>Questionnaire, Evaluation of QOL (FACT-BMT) before Ruxolitinib induction therapy (= baseline), at confinement to Ruxolitinib continuous therapy and after confinement at 6 months, 1 year, 2 years and 3 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of QOL (MPN-SAF-TSS)</measure>
    <time_frame>baseline, confinement to Ruxolitinib continous therapy, +180d, +1 year, +2 years and +3 years</time_frame>
    <description>Questionnaire, Evaluation of QOL (MPN-SAF-TSS) before Ruxolitinib induction therapy (= baseline), at confinement to Ruxolitinib continuous therapy and after confinement at 6 months, 1 year, 2 years and 3 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>3 years</time_frame>
    <description>Overall survival at 3 years after allogeneic SCT compared to Ruxolitinib continuous therapy in patients without a suit-able donor</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">87</enrollment>
  <condition>Bone Marrow Fibrosis</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with Allogeneic Stem cell Transplantation after 3 months of Ruxolitinib induction therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment with Ruxolitinib continuous therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic stem cell transplantation</intervention_name>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ruxolitinib continuous therapy</intervention_name>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Jakavi</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Symptomatic primary myelofibrosis or myelofibrosis post polycythaemia vera or&#xD;
             essential thrombocythemia stage intermediate 2- or high-risk according to IPSS or&#xD;
             DIPSS [46] or intermediate 1-risk with high risk cytogenetics, other than normal&#xD;
             karyotype, sole del 20q, del 13q, or sole+9, or transfusion-dependency&#xD;
&#xD;
          2. Patients age: 18 - 70 years at time of inclusion (female and male)&#xD;
&#xD;
          3. Patients understand and voluntarily sign an informed consent form&#xD;
&#xD;
          4. Platelet count ≥ 50 x 109/L&#xD;
&#xD;
          5. No prior Ruxolitinib treatment&#xD;
&#xD;
          6. ECOG ≤ 2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Severe renal, hepatic, pulmonary or cardiac disease, such as:&#xD;
&#xD;
               -  Total bilirubin, SGPT or SGOT &gt; 3 times upper the normal level&#xD;
&#xD;
               -  Left ventricular ejection fraction &lt; 30 %&#xD;
&#xD;
               -  Creatinine clearance &lt; 30 ml/min&#xD;
&#xD;
               -  DLCO &lt; 35 % and/or receiving supplementary continuous oxygen&#xD;
&#xD;
          2. Positive serology for HIV&#xD;
&#xD;
          3. Pregnant or lactating women (positive serum pregnancy test)&#xD;
&#xD;
          4. Age &lt; 18 and ≥ 71 years.&#xD;
&#xD;
          5. Uncontrolled invasive fungal infection at time of screening (baseline)&#xD;
&#xD;
          6. Serious psychiatric or psychological disorders&#xD;
&#xD;
          7. Participation in another study with ongoing use of unlicensed investigational product&#xD;
             from 28 days before study enrollment&#xD;
&#xD;
          8. Transformation to AML&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolaus Kröger, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Hamburg-Eppendorf</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitätsklinkum Aachen</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HELIOS Klinikum Berlin-Buch</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinkum Halle</name>
      <address>
        <city>Halle (Saale)</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Jena</name>
      <address>
        <city>Jena</city>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin der Johannes Gutenberg-Universität Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johannes Wesling Klinikum Minden</name>
      <address>
        <city>Minden</city>
        <zip>32429</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster</name>
      <address>
        <city>Munster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Nürnberg</name>
      <address>
        <city>Nürnberg</city>
        <zip>90419</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert-Bosch-Krankenhaus Stuttgart</name>
      <address>
        <city>Stuttgart</city>
        <zip>70376</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Tübingen</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinkum Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 22, 2017</study_first_submitted>
  <study_first_submitted_qc>November 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2017</study_first_posted>
  <last_update_submitted>August 20, 2021</last_update_submitted>
  <last_update_submitted_qc>August 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myelofibrosis, Myeloproliferative Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Primary Myelofibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

